Cohance FY26 Growth: Niche Tech, CDMO, Chemicals

  Published 7 months ago

Cohance's niche tech sales rise, pharma CDMO grows, specialty chemicals and API+ see strong gains.

  • Niche modalities like ADCs, oligonucleotides boost revenue, targeting mid‑20s percent FY26 for future growth targets.
  • Pharma CDMO revenue up over 30% excluding de‑stocking, driven by strong commercial execution and innovation.
  • Specialty chemicals rise 28% on AgChem recovery; API+ climbs 19% with new launches driving profits.

You might like these

Jyoti CNC Automation Reports Strong Growth

JSW Wins 30‑Year Kolkata Dock Deal

Waaree Solar Secures $586 MW US Order

Rupee Near Record Low, Tracks Oil, Asia FX

Zee Shares Drop on Weak Q1 Results

GMDC Rare‑Earth Rally, Valuation Caution

Tesla Launches Model Y in India

News that matters the most ⚡